RAF1

ENSG00000132155
Target class
Kinase
Chromosome
3
Approved drugs
3
Clinical candidates (approved and in development)
10

Approved drugs
3
ClinGen gene-disease validity
Definitive
Clinical candidates (approved and in development)
10

Chemical probe available
Yes

Target name
RAF1
Gene name
Raf-1 proto-oncogene, serine/threonine kinase
Gene symbol
RAF1
Protein name
RAF proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1) (Proto-oncogene c-RAF) (cRaf) (Raf-1)

  • Raf-1
  • c-Raf
  • CRAF

Gene biotype
Protein coding
Gene family
Mitogen-activated protein kinase kinase kinases|RAF family
Target class
Kinase
Target type
Human gene

Tissues expressed in
54
Protein localisation evidence grade
Supported
Highest tissue expression
152.17
Tissue specificity (Gini)
0.252
Tissue specificity (tau)
0.463

KEGG gene identifiers
  • hsa:5894
Protein interaction confidence
0.89816
Protein interaction partners
100

  • R-HSA-2672351
  • R-HSA-392517
  • R-HSA-430116
  • R-HSA-5621575
  • R-HSA-5673000
  • R-HSA-5674135
  • R-HSA-5674499
  • R-HSA-5675221
  • R-HSA-6802946
  • R-HSA-6802948
  • R-HSA-6802952
  • R-HSA-6802955
  • R-HSA-9649948
  • R-HSA-9656223
  • R-HSA-9726840
  • R-HSA-9726842
  • R-HSA-9732724

End position
12664201
Start position
12582101
Chromosome
3
Strand
Reverse

Ensembl gene ID
ENSG00000132155
HGNC ID
HGNC:9829
www.genenames.org
NCBI Gene ID
5894
UniProt ID
P04049

  • Cytoplasm. Cell membrane. Mitochondrion. Nucleus. Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and membranes. Phosphorylation at Ser-259 impairs its membrane accumulation. Recruited to the cell membrane by the active Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantly localized at the nucleus.
  • Cytosol
  • Plasma membrane

Tissue specificity (tau)
0.462608
Expression inequality (Gini)
0.252189

Expression in transcripts per million

Muscle - Skeletal
152.17
Artery - Tibial
139.42
Brain - Cerebellar Hemisphere
134.87
Whole Blood
131.14
Ovary
129.4

Expression in transcripts per million

  • Muscle - Skeletal152.17
  • Artery - Tibial139.42
  • Brain - Cerebellar Hemisphere134.87
  • Whole Blood131.14
  • Ovary129.4
  • Artery - Aorta128.08
  • Uterus127.87
  • Brain - Cerebellum126.8
  • Thyroid126.78
  • Cervix - Ectocervix121.59
  • Cells - Cultured fibroblasts121.16
  • Artery - Coronary120.56
  • Nerve - Tibial117.22
  • Cervix - Endocervix115.79
  • Fallopian Tube110.37
  • Cells - EBV-transformed lymphocytes108.27
  • Skin - Sun Exposed (Lower leg)107.99
  • Lung106.76
  • Vagina103.88
  • Skin - Not Sun Exposed (Suprapubic)101.78
  • Bladder99.15
  • Esophagus - Gastroesophageal Junction97.04
  • Spleen94.88
  • Esophagus - Muscularis94.16
  • Prostate93.81

And 29 more, listed on the interactive page.

  • heart disease

    Studies

    • preclinical: Important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Anti-apoptotic; preserves left ventricular function under stress. Knockout mouse model: left ventricular dysfunction and heart failure in the absence of additional stress; Dominant negative transgenic mouse model: reduced hypertrophy but left ventricular dysfunction due to cell death

    Biological samples

    • cardiovascular system
    PubMed 21283106
    pubmed.ncbi.nlm.nih.gov

  • regulation of catalytic activity

    Studies

    • biochemical: NVS_ENZ_hRAF1, is one of one assay component(s) measured or calculated from the NVS_ENZ_hRAF1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.

    Biological samples

    • cell-free
    Evidence source
    www.epa.gov

Related records

Trials (1,110)

Drugs (12)